Xoma (US) LLC

Xoma Technology Ltd.

Kiranjit Kaur Ahluwalia

Toshihiko Takeuchi

Kirk William Johnson

Daniel H Bedinger

Hassan Issafras

Raphael D Levy

Amer M Mirza

Agnes Choppin Holmes

Rachel A Hunt

Robyn Cotter

John Corbin

Ou Li

Chung-Leung Chan

Paul Rubin

Ira Goldfine

Raphael David Levy

The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.

Methods and materials for enhancing functional protein expression in bacteria

Growing community of inventors

Berkeley, CA, United States of America

Kiranjit Kaur Ahluwalia